Table 3.
Performance of TREAT-B and Simplified WHO to select patients eligible for anti-HBV therapy in subgroup of patients.
| Age<40 years (n = 231) | Age ≥40 years (n = 594) | |||||
|---|---|---|---|---|---|---|
| TREAT-B ≥2 | TREAT-B ≥3 | Simplified WHO | TREAT-B ≥2 | TREAT-B ≥3 | Simplified WHO | |
| AUROC (95% CI) | 0.74 (0.67–0.80) | 0.80 (0.72–0.88) | 0.62 (0.54–0.70) | 0.67 (0.63–0.71) | 0.80 (0.76–0.85) | 0.62 (0.57–0.67) |
| P-value | < 0.001 | < 0.001 | 0.009 | < 0.001 | < 0.001 | < 0.001 |
| Sensitivity | 100% | 71.4% | 70.9% | 94.8% | 71.0% | 71.5% |
| Specificity | 47.3% | 88.5% | 60.8% | 39.2% | 89.1% | 59.9% |
| PPV | 39.2% | 67.8% | 39.4% | 35.5% | 69.6% | 39.9% |
| NPV | 100% | 90.1% | 85.3% | 95.6% | 89.7% | 85.0% |
| HBeAg positive (n = 154) | HBeAg negative (n = 671) | |||||
| AUROC (95% CI) | 0.81 (0.74–0.88) | 0.77 (0.69–0.85) | 0.61 (0.52–0.70) | 0.67 (0.63–0.72) | 0.83 (0.79–0.87) | 0.61 (0.56–0.66) |
| P-value | < 0.001 | < 0.001 | 0.018 | < 0.001 | < 0.001 | < 0.001 |
| Sensitivity | 92.9% | 55.7% | 79.7% | 97.9% | 78.1% | 97.9% |
| Specificity | 69.0% | 97.6% | 47.5% | 37.0% | 87.6% | 36.0% |
| PPV | 71.4% | 95.1% | 56.7% | 30.2% | 63.7% | 34.3% |
| NPV | 92.1% | 72.6% | 73.1% | 98.5% | 93.5% | 86.7% |
| Body mass index<25 kg/m2 (n = 520) | Body mass index ≥25 kg/m2 (n = 305) | |||||
| AUROC (95% CI) | 0.69 (0.65–0.74) | 0.77 (0.72–0.83) | 0.59 (0.54–0.66) | 0.62 (0.55–0.69) | 0.81 (0.75–0.87) | 0.61 (0.54–0.68) |
| P-value | < 0.001 | < 0.001 | 0.002 | 0.003 | < 0.001 | 0.004 |
| Sensitivity | 96.6% | 63.8% | 65.5% | 96.2% | 79.7% | 79.2% |
| Specificity | 42.4% | 91.0% | 58.6% | 27.0% | 82.6% | 52.8% |
| PPV | 37.7% | 71.8% | 37.0% | 36.9% | 67.0% | 44.2% |
| NPV | 97.1% | 87.4% | 82.0% | 94.1% | 90.2% | 84.3% |
AUROC, area under the receiver operating curve; PPV, positive predictive value; NPV, negative predictive value; 95% CI, 95% confidence interval.